ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified.

Francken, Anne Brecht; Hoekstra-Weebers, Josette E H M; Deckers, Eric; Hoekstra, Harald J

Francken, Anne Brecht; Hoekstra-Weebers, Josette E H M; Deckers, Eric; Hoekstra, Harald J.

Afiliação

Francken AB; Department of Surgical Oncology, Isala Clinics, Zwolle, The Netherlands.
Hoekstra-Weebers JEHM; Wenckebach Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Deckers E; Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Hoekstra HJ; Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. h.j.hoekstra@umcg.nl.

Ann Surg Oncol ; 27(5): 1418-1419, 2020 May.

Article em En | MEDLINE | ID: mdl-31482389

Assuntos

Melanoma/economia; Neoplasias Cutâneas/economia; Biomarcadores; Análise Custo-Benefício; Custos de Cuidados de Saúde; Humanos; Melanoma/terapia; Prognóstico; Neoplasias Cutâneas/terapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Ann Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google